Director

John Doux, M.D., M.B.A.

Dr. Doux is a board-certified dermatologist and a Fellow of the American Academy of Dermatology. Since 2004, he has served as an analyst at Palo Alto Investors LP, a physician-led healthcare focused investment firm, where he has been involved in investments in several leading publicly traded companies developing and commercializing novel therapies for serious, rare diseases. Dr. Doux co-founded the Dermatology Summit and the Dermatology Innovation Forum and previously served on the conference’s Board of Directors. Dr. Doux serves as a board trustee for Pachyonychia Congenita Project and as a director on the Board of Directors of Kamari Pharma. He has also served on the boards of multiple biotechnology companies, including Ceptaris Therapeutics, which developed VALCHLOR® for cutaneous T-cell lymphoma and was acquired by Actelion. Dr. Doux previously served on Palvella’s Board of Directors from 2019 to 2022. He maintained a clinical practice in medical and surgical dermatology from 1999 to 2016.

Dr. Doux received his B.S. with Distinction and M.D. from Stanford University and conducted early dermatology research as a Howard Hughes Medical Institute Student Fellow in the laboratory of Dr. David T. Woodley. He completed his internship in internal medicine at Brigham and Women’s Hospital and his dermatology residency at Stanford University Medical Center, where he later served as Chief Resident. He also earned an M.B.A. from The Wharton School of the University of Pennsylvania, where he was named a Palmer Scholar.